FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel. Pete O'Heeron, Founder and CEO, will represent the company.

FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. The company boasts over 160 issued and pending patents. Their presentation will be available on-demand to registered attendees starting September 9, 2024, at 7 a.m. Eastern Time.

Interested parties can find more information on FibroBiologics' website or by contacting info@fibrobiologics.com.

News Market Reaction – FBLG

+12.37%

1 alert

+12.37% News Effect

On the day this news was published, FBLG gained 12.37%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

HOUSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the H.C. Wainwright 26^th Annual Global Investment Conference taking place September 9-11 at the Lotte New York Palace Hotel in New York City.

FibroBiologics’ presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 9, 2024, at 7 a.m. Eastern Time.

For more information, please visit FibroBiologics' website or email FibroBiologics at info@fibrobiologics.com.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
212-845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

When and where is FibroBiologics (FBLG) presenting at the H.C. Wainwright conference?

FibroBiologics (FBLG) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, at the Lotte New York Palace Hotel in New York City.

What time will FibroBiologics' (FBLG) presentation be available on-demand?

FibroBiologics' (FBLG) presentation will be available on-demand to registered attendees starting September 9, 2024, at 7 a.m. Eastern Time.

What is the main focus of FibroBiologics' (FBLG) research?

FibroBiologics (FBLG) focuses on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials.

How many patents does FibroBiologics (FBLG) have?

FibroBiologics (FBLG) has over 160 issued and pending patents related to their biotechnology research and development.